This form of stem cell therapy effectively alleviates intestinal inflammation in experimental DSS-induced colitis by activating the Mer/PI3K/Akt/GSK3β pathway and promoting macrophage M2 polarization [105]. The gene discussed is AKT1; the disease is colitis.